Pipeline & Disease Focus

Other Assets / Indications

Cytokines are valid targets for therapeutic intervention in immune diseases. However, it has been scientifically documented that more than one cytokine pathway is dysregulated in any immune disease which will pose a challenge for single mAB therapy strategy. To circumvent this problem, Bioniz has developed peptides that each specifically inhibits more than one cytokine, broadening the therapeutic efficacy of the peptide as compared to single mAB therapy. Each peptide selectively targets different set of cytokines that are critical in different immune diseases. The following peptides are under investigation in different animal models of the immune diseases:

- BNZ132-2 -> Celiac Disease and Inflammatory Bowl Disease (IBD)
- BNZ132-3 -> Allergy and Asthma
- BNZ132-1 -> Multiple Sclerosis (MS) & Cancer Immunotherapy

Bioniz is advancing its lead asset (BNZ132-1) into clinical trials and towards commercialization while continuing its cutting edge research and development on its other assets for different indications. Bioniz is interested in partnerships and collaborations with domestic and international pharmaceutical companies to assist us advance our programs closer to clinical studies.